Reema Singh | Hematology | Best Researcher Award

Ms. Reema Singh | Hematology | Best Researcher Award

RAJIV GANDHI CANCER INSTITUTE & RESEARCH CENTRE- India

Author Profile

Early Academic Pursuits 🎓

Reema Singh embarked on her academic journey with a focus on the sciences, beginning with a Bachelor’s degree in Biochemistry from Institute of Home Economics, Delhi University, Delhi. (2012 – 2015). This foundational education in biochemistry provided her with a strong base in the principles of biological and chemical processes. Motivated by a keen interest in the application of these principles in clinical settings, she pursued a Master’s degree in Clinical Research at a prestigious institution, completing her studies between 2015 and 2017. This advanced education equipped Reema with the specialized knowledge required for a career in clinical research, marking the beginning of her journey into the field where she would make significant contributions.

Professional Endeavors 🔬

Reema Singh’s career began with an internship at PGIMER Dr. RML Hospital, New Delhi, in 2016, where she trained in Clinical Research and Biostatistics. This experience was further supplemented by a training program at Sun Pharmaceutical Industries Limited in Clinical Pharmacology. These early roles provided her with a comprehensive understanding of clinical research methodologies and pharmacological principles.Her professional career officially began at Rajiv Gandhi Cancer Institute & Research Centre, where she took on multiple roles over the years. Starting as a Clinical Research Coordinator in August 2017, she quickly advanced to roles including Senior Clinical Research Coordinator, Clinical Research Team Lead, and Senior Medical Writer. These positions allowed her to develop and refine her skills in clinical research management, medical writing, and team leadership.In January 2023, Reema was promoted to the position of Head of the Clinical Research Department at Rajiv Gandhi Cancer Institute & Research Centre. In this role, she leads a team of researchers and clinical trial coordinators, overseeing the execution of clinical studies and ensuring compliance with regulatory guidelines. Her responsibilities also include writing and editing scientific documents, mentoring junior staff, and managing clinical trials.

Contributions and Research Focus 🔍

Reema Singh’s primary focus has been on clinical research within the field of hematology. Her contributions include overseeing and coordinating clinical trials, developing research protocols, and ensuring the adherence to Good Clinical Practice (GCP) guidelines. She has been involved in numerous high-impact projects, including a comparative analysis of chemotherapy treatments and a risk and response adapted approach for myeloma treatment, both of which have been published in leading journals such as Blood.Her role involves creating detailed and scientifically accurate documentation, such as clinical study protocols and reports, which are crucial for the integrity and success of clinical trials. She has also contributed to the development of databases and reports that support research activities, demonstrating her ability to handle complex data management tasks.

Accolades and Recognition 🏆

Reema Singh’s professional excellence has been recognized through her work at esteemed institutions and her contributions to significant clinical research projects. Her ability to handle multiple tasks, from writing high-quality scientific documents to managing large-scale research projects, has earned her a reputation as a reliable and skilled clinical research professional. Her publications in reputable journals highlight her expertise and the impact of her research on the field of hematology.

Impact and Influence 🌟

Reema Singh’s work has had a considerable impact on the field of clinical research, particularly in hematology. Her leadership and contributions have influenced the direction of clinical trials and research projects, improving the standards of practice within her department. Her role as a mentor and leader has helped shape the careers of many junior researchers and clinicians, further extending her influence in the field.Her efforts in managing and coordinating complex research studies have contributed to advancements in cancer treatment, showcasing her commitment to improving patient outcomes through scientific research. By ensuring the adherence to ethical standards and regulatory guidelines, Reema has played a pivotal role in maintaining the integrity and quality of clinical trials.

Legacy and Future Contributions 🚀

Reema Singh’s legacy in the field of clinical research is marked by her dedication to excellence and her contributions to the advancement of cancer research. Her role as Head of the Clinical Research Department at Rajiv Gandhi Cancer Institute & Research Centre underscores her leadership and commitment to the field.Looking ahead, Reema aims to continue her work in clinical research, focusing on innovative approaches to cancer treatment and improving clinical trial methodologies. Her future contributions will likely involve pioneering research projects and advancing the field through her expertise in medical writing, data management, and team leadership.Reema Singh’s career is a testament to her dedication and skill in clinical research, and her ongoing work promises to bring further advancements in the field, continuing to impact and improve patient care.

Citations

A total of 22 citations for his publications, demonstrating the impact and recognition of his research within the academic community.

  • Citations         22
  • h-index           14
  • i10-index        03

Notable Publications 

  • Real World Outcome of B ALL with t(1; 19)(q23; p13)/TCF3::PBX1 in Adolescents and Adults Treated with Intensive Regimes
    • Authors: Panda, T., Rainchwar, S., Singh, R., Bhurani, D., Agrawal, N.
    • Journal: Leukemia Research
    • Year: 2024.
  • Low Fixed Dose Pembrolizumab with Gemcitabine, Vinorelbine, Liposomal Doxorubicin (Pembro100-GVD) as an Effective Salvage Regimen in Relapsed Refractory Classical Hodgkin’s Lymphoma and Primary Mediastinal B Cell Lymphoma
    • Authors: Panda, T., Rainchwar, S., Halder, R., Bhurani, D., Agrawal, N.
    • Journal: Annals of Hematology
    • Year: 2024.
  • HIV Associated Lymphomas: A Double-Edged Sword
    • Authors: Singh, R., Kapoor, J., Panwar, N., Agrawal, N., Bhurani, D.
    • Journal: Indian Journal of Hematology and Blood Transfusion
    • Year: 2024.
  • FLAG Based vs. Standard 3 + 7 Induction Therapy in Treatment Naïve Acute Myeloid Leukemia: Time to Think “Beyond Anthracyclines”
    • Authors: Shaikh, M.R., Singh, B., Halder, R., Mirgh, S.P., Bhurani, D.
    • Journal: Leukemia Research
    • Year: 2023.
  • End of Induction MRD Assessment Based Early Treatment Intensification with Novel Agents in ETP-ALL – May Be the Way Forward
    • Authors: Patra, P.C., Rainchwar, S., Singh, R., Agrawal, N., Pramanik, S.
    • Journal: Blood Research
    • Year: 2023.